18F-FDG PET/CT Imaging: Normal Variants, Pitfalls, and Artifacts Musculoskeletal, Infection, and Inflammation

Olwethu Mbakaza* and Mboyo-Di-Tamba Willy Vangu

Department of Nuclear Medicine and Molecular Imaging, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa

18F-FDG PET/CT is an integral part of modern-day practice, especially in the management of individuals presenting with malignant processes. The use of this novel imaging modality in oncology has been rapidly evolving. However, due to its detection of cellular metabolism, it is not truly tumor specific. 18F-FDG is also used in the detection of infective and inflammatory disorders. One of the challenges experienced with 18F-FDG PET/CT imaging is the correct differentiation of abnormal uptake that is potentially pathologic, from physiological uptake. Imaging readers, particularly the nuclear physicians, therefore need to be aware of normal physiological variants of uptake, as well as potential pitfalls and artifacts when imaging with 18F-FDG. This is true for musculoskeletal uptake, where more than often, infective and inflammatory processes should not be mistaken for malignancy. This article aims to provide a pictorial review and analysis of cases that depict musculoskeletal, infective, and inflammatory uptake as normal variants, pitfalls, and artifacts on 18F-FDG PET/CT imaging. The impact of this article is to help in the minimizing of poor imaging quality, erroneous interpretations and diminishes misdiagnoses that may impact on the adequate management of patients with undesirable consequences.

Keywords: 18F-FDG PET/CT, musculoskeletal, pitfalls, artifacts, normal variants, inflammation, infection

INTRODUCTION

Flourine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is today widely used in the management of oncology patients. Due to its non-specific nature for malignant lesions, 18F-FDG may also be used to detect processes involved in infection and inflammation. Therefore, issues related to pitfalls and normal variants should be kept in mind during imaging interpretation. This article will be focusing on imaging illustration pitfalls and normal variants related to musculoskeletal, infection, and inflammation with limited narrative related to the topic. Broader narrative on normal variants, pitfalls, and artifacts for 18F-FDG PET/CT in general may be found in other published articles.
FDG Physiology

FDG is a glucose analog and thus follows the similar fate as glucose in living tissues. Glucose enters the cell through glucose transporters, gets phosphorylated to glucose-6 phosphate by hexokinase, and further metabolism occurs (1). FDG, however, does not get metabolized further once it is phosphorylated to glucose-6 phosphate and is trapped inside the cell. FDG uptake inside the cells is dependent on glucose transporters, which indirectly get affected by serum glucose level, insulin level, and cellular demand (1).

The quantitative measurement of $^{18}$F-FDG accumulation in tissues has not yet been standardized (2). The commonly used parameter for quantitative measurement is the maximum standardized uptake value (SUVmax). Related quantitative parameters include, among others, the SUVpeak, SUVmean, total lesion glycolysis (TLG), and metabolic tumor volume (MTV) (2).

Pathophysiology of $^{18}$F-FDG in Malignancy

$^{18}$F-FDG PET/CT plays a pivotal role in imaging malignant processes, and has been used to detect and evaluate both solid

![FIGURE 1](image_url)

**FIGURE 1** | Combined PET/CT and CT images of a 54-year-old man with esophageal melanoma. He has multiple sites of skeletal uptake attributable to recent trauma: in the R lateral 8th and 9th ribs (A,B), superior pubic ramus (C,D), and inferior pubic ramus (E,F).
and haematological malignancies (3). FDG, as a glucose analog, adds a benefit of depicting functional information—hence metabolic abnormalities before anatomic changes occur (4). This is based on increased glucose uptake and increased glycolytic activity in malignant cells (3).

18F-FDG PET/CT is a very useful tool in the diagnosis and follow-up of malignant processes, due to the sensitivity of the tracer and imaging modality. It aids in upstaging and downstaging of the disease extent, which leads to a change in disease management (5). 18F-FDG PET/CT is useful in the detection of malignant disease with high sensitivity; it does, however, have the limitation of low specificity—in that a highly metabolically active lesion may be indicative of malignant, reactive, or reparative changes, and infective or inflammatory changes (1). To increase its specificity, it may be of importance to review the patient’s clinical history, particularly oncologic history, such as treatment and procedures. This is in addition to other imaging modalities, together with laboratory changes (3). This clinical information may be in a prepared questionnaire or obtained in person. Despite these measures, there will be lesions with indeterminate uptake of tracer on 18F-FDG PET/CT (3).

**Biodistribution of FDG**
The physiological biodistribution of FDG is the brain (gray matter), vocal cords, tonsils, thymus, skeletal muscle, brown fat, left ventricular myocardium, bowel, liver, spleen, kidneys, ureter, urinary bladder, and bone marrow (6). Physiological uptake in the gingival, genioglossus, and pterygoid muscles has also been described (7).

Various (musculoskeletal, infective, and inflammatory) processes that may be mistakenly interpreted as malignant changes will be discussed by way of a pictorial review below.

**Musculoskeletal Pitfalls**

**Multiple Sites of Skeletal Trauma**
Bone metastases may be represented by discrete foci of uptake in bone, which is a similar presentation as fractures (7). A fracture line may also be missed if the window displayed is in the CT soft tissue window, as opposed to bone window (6). Patients with underlying malignancy who have received chemotherapy with or without radiation therapy can also present with pelvic insufficiency fractures. Additional risk factors to this include corticosteroid therapy, osteoporosis, rheumatoid arthritis, and metabolic bone disease (7). A thorough history of trauma needs to be ascertained from the patient as per case in Figure 1.

**Inflammatory Pitfalls**

**Pathophysiology of 18F-FDG in Inflammation**
Inflammation is the tissues’ response to injury, which may include irritation, infection, or trauma. The body responds...
to inflammatory stimuli with a cascade of events, which includes local hyperemia, release of proteins such as fibrin and immunoglobulins, leakage of fluids, and infiltration of inflammatory cells (8). Inflammation exhibits $^{18}$F-FDG uptake due to the recruitment of activated white blood cells (neutrophils and lymphocytes), which have high affinity for glucose transporters, especially GLUT 1 and GLUT 3 (1, 8). There is also upregulation of GLUT-1 transporters in macrophages, which constitute a major component in the body's response to infection (1). There is also increased affinity to $^{18}$F-FDG in inflammation through cytokines and growth factors (8). Increased uptake because of infection or inflammation on $^{18}$F-FDG PET/CT cannot be distinguished from tumor uptake.

Figures 2–4 show patterns of $^{18}$F-FDG uptake consistent with inflammation rather than malignant disease.

**Infection**

Cervical carcinoma is an AIDS-defining illness (9, 10). Immunocompromised women living with HIV with concomitant human papillomavirus infection have a higher chance of developing pre-invasive lesions, which lead to cervical carcinoma (8). $^{18}$F-FDG PET is of use in the diagnosis, staging, and detection of metastasis and in post-treatment monitoring of several AIDS-defining malignancies (11). However, caution should be taken, as immunosuppressed patients are also prone to infection. Sites of infection may mimic metastatic disease as in the case of the 38-year-old woman with a stage IIIIB cervical carcinoma in aforementioned Figure 5. This is a clinical situation of an immunocompromised individual with retroviral disease on antiretroviral treatment. The psoas collection has radiological features of a cold abscess. Osseous infection may also mimic metastatic disease, as in this case of a 54 year old man with renal cell carcinoma. His combined FDG PET/CT images (Figure 6) showed an intense lesion in the left side of the mandible, which was due to osteomyelitis.

**Musculoskeletal Uptake: Normal Variants**

The major source of energy for skeletal muscles during the resting state is fatty acid oxidation (1). This results in homogeneous uptake of FDG in skeletal muscle. Plasma insulin, however, can increase glucose uptake in skeletal muscle by inducing the translocation of GLUT-4 from the intracellular vesicles to the plasma membrane and can thus result in increased skeletal glucose uptake in postprandial state (1). Voluntary and involuntary muscular activity can result in increased FDG uptake, which may result in a wide variety of seemingly pathological uptake.
Diffuse whole-body muscle uptake may be seen in patients with recent insulin injection, strenuous exercise involving strenuous muscle groups, and recent meal consumption (1).

Activities such as talking can cause increased uptake in bilateral vocal cords. Muscular uptake involving the upper extremities could result from activities that require the use of skeletal muscle such as turning pages of a book (1).

In individuals who experience muscle exertion, uptake may be seen in different parts of the body (Figure 7). In the same vein, in individuals with chronic obstructive pulmonary disease, due to difficult breathing and/or excessive coughing, intercostal muscular and diaphragmatic uptake may be seen.

**Osteodegenerative Changes and Arthropathies**

Active inflammatory arthropathies because of psoriasis, rheumatoid arthritis, gout, and ankylosing spondylitis may mimic disease. The uptake of tracer in these conditions is dependent on the presence of synovitis (7). Figure 8 shows an 18F-FDG PET/CT study done on a 69-year-old woman with left breast carcinoma, which showed intense uptake in the gleno-humeral joints, with subchondral cystic osteodegenerative changes on CT.

A number of images (Figures 9–12) that represent multiple sites of intense FDG activity in the skeleton are displayed below. All changes were due to osteodegenerative changes.
In a study evaluating cervical, thoracic, and lumbar spine uptake in 150 patients who underwent $^{18}$F-FDG PET/CT scan, Costelloe et al. found abnormal uptake corresponding to osteodegenerative change in 22% of patients (7). They, however, found a weak correlation between severe osteodegenerative changes and the degree of uptake (7).

**Metallic Artifacts**
Metallic objects such as orthopedic hardware, dental implants, pacemakers, and injection ports attenuate photons, and the degree of attenuation is higher at CT X-ray energy than at PET energy (12). This therefore leads to an overestimation of attenuation, which results in artifactually increased FDG activity in CT attenuation-corrected PET images (12) (Figure 13). If an artifact is suspected, then confirmation is made by evaluating the non-attenuation-corrected images. This is to prevent erroneous misinterpretation of increased uptake as disease.

**CONCLUSION**
$^{18}$F-FDG PET/CT is a very useful tool in the diagnosis and follow-up of malignant disease due to the high sensitivity of this imaging modality. Its specificity, however, may be reduced by the presence of musculoskeletal, infective, and inflammatory pitfalls. It is important to always be wary of these potential pitfalls as they may influence the diagnosis and course of management of the patient. The patient's clinical history is a mandatory step in the navigation of PET/CT images.

**AUTHOR CONTRIBUTIONS**
OM responsible for the data collection, data sources, and write-up of the article. M-D-TV responsible for conceptualization of the topic and write-up and review of the article. Both authors contributed to the article and approved the submitted version.
FIGURE 7 | Combined PET/CT images of a 67-year-old woman with anal carcinoma. There is diffuse uptake in the skeletal muscles of the neck (A), chest (B), and upper limbs (C)—related to muscular exertion.
**FIGURE 8** | A 69-year-old woman with left breast carcinoma. Combined PET/CT (A) and PET maximum intensity projection (MIP) (C) images show intense uptake in the gleno-humeral joints, with subchondral cystic osteodegenerative changes on CT (B).
FIGURE 9 | (A) A 68-year-old woman with basal cell carcinoma of the left breast. Combined PET/CT images show intense uptake in the right facet joint of L3/L4, which is consistent with osteodegenerative change. (B-a-c) Same patient as in (A) above with increased uptake in the spinous process.

FIGURE 10 | 56 year old woman with ovarian Ca. Combined PET/CT and PET images show intense uptake in the left acromio-clavicular joint, which is osteodegenerative.

FIGURE 11 | 50 year old man with melanoma of the scalp. PET and Combined PET/CT images show intense uptake in the left sternoclavicular joint, which is osteodegenerative.
Mbakaza and Vangu

Musculoskeletal, Infection, and Inflammation Pitfalls

FIGURE 12 | 59 year old woman with breast Ca. Combined PET/CT and PET images show intense uptake in the left facet joint of L5/S1, which is osteodegenerative.

FIGURE 13 | A 56-year-old man with sinonasal carcinoma of the hard palate. Combined PET/CT (A) and CT (B) images show intense uptake related to a metallic artifact in the left anterior thigh.

REFERENCES

1. Parida GK, Roy SG, Kumar R. FDG-PET/CT in skeletal muscle: pitfalls and pathologies. Semin Nucl Med. (2017) 47:362–72. doi: 10.1053/j.semnuclmed.2017.02.003
2. Kawada K, Iwamoto M, Sakai Y. Mechanisms underlying 18F-fluorodeoxyglucose accumulation in colorectal cancer. World J Radiol. (2016) 8:880–6. doi: 10.4329/wjr.v8.i11.880
3. Rahman WT, Wale DJ, Viglianti BL, Townsend DM, Manganaro MS, Gross MD, et al. The impact of infection and inflammation in oncologic 18F-FDG PET/CT imaging. Biomed Pharmacother. (2019) 117:109168. doi: 10.1016/j.biopha.2019.109168
4. Németh Z, Boér K, Borbély K. Advantages of F-18 FDG PET/CT over conventional staging for sarcoma patients. Pathol Oncol Res. (2019) 25:131–6. doi: 10.1007/s12253-017-0325-0
5. Fonti R, Consosn M, Del Vecchio S. PET/CT in radiation oncology. Semin Oncol. (2019) 46:202–9. doi: 10.1053/j.seminoncol.2019.07.001
6. Mettler FA, Guiberteteau MJ. Essentials of Nuclear Imaging 6th Edn. Saunders (2012).

7. Costelloe CM, Murphy WA Jr, Chasen BA. Musculoskeletal pitfalls in 18F-FDG PET/CT: pictorial review. AJR Am J RoentGenol. (2009) 193(3 Suppl): WS1–13. doi: 10.2214/AJR.07.7138
8. Metser U, Even-Sapir E. Increased 18F-Fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): Accumulated data from four years of experience with PET/CT. Semin Nucl Med. (2007) 37:206–22. doi: 10.1053/j.semnuclmed.2007.01.001
9. UNAIDS. Available online at: https://www.unaids.org/en/resources/presscentre/featurestories/2018/october/cervical-cancer-and-hiv (accessed November 29, 2021).
10. WHO. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children. Geneva: WHO (2007).
11. Davison JM, Subramaniam RM, SuraSi DS, Cooley T, Mercier G, Peller J. FDG PET/CT in patients with HIV. AJR. (2011) 197:284–94. doi: 10.2214/AJR.10.6332
12. Wang X, Koch S. Positron emission tomography/computed tomography potential pitfalls and artifacts. *Curr Probl Diagn Radiol.* (2009) 38:156–69. doi: 10.1067/j.cpradiol.2008.01.001

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Mbakaza and Vangu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.